DS-8201 is an HER2-targeted ADC with a potent topoisomerase I inhibitor payload which presents bystander killing [41] and showed antitumor efficacy against several breast cancer models with low HER2 expression [42]. This evidence concerns the gene ERBB2 and breast carcinoma.